# MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery

> **NCT01425879** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 8 (actual)

## Conditions studied

- Advanced Adult Hepatocellular Carcinoma
- Localized Non-Resectable Adult Liver Carcinoma
- Recurrent Adult Liver Carcinoma
- Recurrent Gallbladder Carcinoma
- Stage IV Distal Bile Duct Cancer
- Stage IV Gallbladder Cancer
- Unresectable Extrahepatic Bile Duct Carcinoma
- Unresectable Gallbladder Carcinoma

## Interventions

- **DRUG:** Akt Inhibitor MK2206
- **OTHER:** Diagnostic Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT01425879
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2013-05
- **Final completion:** 2014-05
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2016-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01425879

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01425879, "MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01425879. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*